ACA 125

Identification

Generic Name

ACA 125

DrugBank Accession Number

DB05489

Background

An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.

This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells. Antiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor are suited to this approach.

To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported.

Type

Small Molecule

Groups

Investigational

Synonyms

Not Available

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Mechanism of action

To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. ACA 125 (Ab2) showed high affinity for the paratope of Abl. Binding of Ab2 to Abl is completely inhibited by the nominal antigen. Application of fragments of ACA 125 to rats lead to an anti-CA 125 immunity by production of IgG and IgM antiantiidiotypic antibodies (Ab3) that bind to both ACA 125 and CA 125.

Target	Actions	Organism
UTyrosine-protein kinase transforming protein Abl	Not Available	Abelson murine leukemia virus

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Chemical Identifiers

UNII: Not Available
CAS number: Not Available
InChI Key: Not Available
InChI: Not Available
IUPAC Name: Not Available
SMILES: Not Available

References

General References

Reinartz S, Wagner U, Giffels P, Gruenn U, Schlebusch H, Wallwiener D: Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125. Cancer Immunol Immunother. 2000 Jul;49(4-5):186-92. [Article]
Schlebusch H, Wagner U, Grunn U, Schultes B: A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma. 1995 Apr;14(2):167-74. [Article]

External Links